Вопросы вирусологии. 2017; 62: 162-168
ДИМЕРНЫЕ БИСБЕНЗИМИДАЗОЛЫ ПОДАВЛЯЮТ ИНФЕКЦИИ, ВЫЗВАННЫЕ ВИРУСОМ ПРОСТОГО ГЕРПЕСА И ЦИТОМЕГАЛОВИРУСОМ ЧЕЛОВЕКА, В КЛЕТОЧНЫХ КУЛЬТУРАХ
https://doi.org/10.18821/0507-4088-2017-62-4-162-168Аннотация
Список литературы
1. Looker K.J., Magaret A.S., May M.T., Turner K.M., Vickerman P., Gottlieb S.L. et al. Global and Regional Estimates of Prevalent and Incident Herpes Simplex Virus Type 1 Infections in 2012. PLoS One. 2015; 10(10): e0140765.
2. James S.H., Kimberlin D.W. Neonatal herpes simplex virus infection: epidemiology and treatment. Clin. Perinatol. 2015; 42(1): 47-59.
3. Barrett M.P., Gemmell C.G., Suckling C.J. Minor groove binders as anti-infective agents. Pharmacol. Ther. 2013; 139: 12-23.
4. Wilson W. D., Nguyen B., Tanious F. A., Mathis A., Hal J.E., Stephens C.E. et al. Dications that target the DNA minor groove: compound design and preparation, DNA interactions, cellular distribution and biological activity. Curr. Med. Chem. Anticancer. Agents. 2005; 5(4): 389-408.
5. Мейхи Б. Вирусология. Методы: Пер. с англ. М.: Мир; 1988
6. Latt S.A. Optical studies of metaphase chromosome organization. Annu. Rev. Biophys. Bioeng. 1976; (5): 1-37.
7. Teng M.K., Usman N., Frederick C.A., Wang A.H. The molecular structure of the complex of Hoechst 33258 and the DNA dodecamer d(CGCGAATTCGCG). Nucleic. Acids. Res. 1988; (16): 2671.
8. Vega M.C., Saez I.G., Aymami J., Eritja R., van der Marel G.A., van Boom J.H., et al. Three-dimensional crystal structure of the A-tract DNA dodecamer d(CGCAAATTTGCG) complexed with the minor-groove-binding drug Hoechst 33258. Eur. J. Biochem. 1994; 222: 721.
9. Chiang S.Y., Welch J.J., Rauscher F.J., Beerman T.A. Effects of minor groove binding drugs on the interaction of TATA box binding protein and TFIIA with DNA. Biochemistry. 1994; (33): 7033-40.
10. Chiang S.Y., Welch J.J., Rauscher F.J., Beerman T.A. Effect of DNA-binding drugs on early growth response factor-1 and TATA box-binding protein complex formation with the herpes simplex virus latency promoter. J. Biol. Chem. 1996; 271: 23999-4004.
11. Chen A.Y., Yu C., Gatto B., Liu L.F. DNA minor groove-binding ligands: a different class of mammalian DNA topoisomerase I inhibitors. Proc. Nat. Acad. Sci. USA. 1993; 90: 8131-5.
12. Zhang X., Zhang S.C., Sun D., Hu J., Wali A., Pass H., et al. New insight into the molecular mechanisms of the biological effects of DNA minor groove binders. PLoS One. 2011; 6(10): e25822.
13. Woynarowski J.M., McHugh M., Sigmund R.D., Beerman T.A. Modulation of topoisomerase II catalytic activity by DNA minor groove binding agents distamycin, Hoechst 33258, and 4’,6-diamidine-2-phenylindole. Mol. Pharmacol. 1989; 35: 177-82.
14. Soderlind K.J., Gorodetsky B., Singh A.K., Bachur N.R., Miller G.G., Lown J.W. Bis-benzimidazole anticancer agents: targeting human tumour helicases. Anticancer. Drug Design. 1999; 14: 19-36.
15. Martin R.F., Broadhurst S., D’Abrew S., Budd R., Sephton R., Reum M., et al. Radioprotection by DNA ligands. Br. J. Cancer Suppl. 1996; 74(27): 99-101.
16. Lyubimova N.V., Coutlas P.G., Yuen K., Martin R.F. In vivo radioprotection of mouse brain endothelial cells by Hoechst 33342. Br. J. Radiol. 2001; 74: 77-82.
17. Сусова О.Ю., Иванов А.А., Моралес Руисс С.С., Лессовая Е.А., Громыко А.В., Стрельцов С.А. и др. Узкобороздочные димерные бисбензимидозолы ингибируют in vitro связывание с ДНК эукариотической ДНК топоизомеразы I. Биохимия. 2010; 75(6): 781-8
18. Cherepanova N.A., Ivanov A.A., Maltseva D.V., Minero A.S., Gromyko A.V., Streltsov S.A., et al. Dimeric bisbenzimidazoles inhibit the DNA methylation catalyzed by the murine Dnmt3a catalytic domain. J. Enzyme Inhib. Med. Chem. 2011; 26(2): 295-300.
19. Tunitskaya V.L., Mukovnya A.V., Ivanov A.A., Gromyko A.V., Ivanov A.V., Streltsov S.A., et al. Inhibition of the helicase activity of the HCV NS3 protein by symmetrical dimeric bis-benzimidazoles. Bioorg. Med. Chem. Lett. 2011; 21(18): 5331-5.
20. Попов К.В., Егорова Е.И., Иванов А.А., Громыко А.В., Жузе А.Л., Большева Н.Л. и др. Димерные бисбензимидозольные красители на основе Hoechst 33258 новые ДНК-специфичные флюорохромы для цитогенетики человека и растений. Биологические мембраны. Журнал мембранной и клеточной биологии. 2008; 25(3): 173-80
21. Looker K.J., Magaret A.S., Turner K.M., Vickerman P., Gottlieb S.L., Newman L.M. Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012. PLoS One. 2015; 10(1): e114989
22. Климова Р.Р., Малиновская В.В., Гусева Т.С., Паршина О.В., Гетия Е.Г., Дегтярева М.В. и др. Влияние герпесвирусных инфекций на уровень провоспалительных цитокинов у недоношенных новорожденных детей. Вопросы вирусологии. 2011; (4): 23-6
23. Moore M.D., Bunka D.H., Forzan M., Spear P.G., Stockley P.G., McGowan I., et al. Generation of neutralizing aptamers against herpes simplex virus type 2: potential components of multivalent microbicides. J. Gen. Virol. 2011; 92(7): 1493-9.
24. Slyker J.A. Cytomegalovirus and paediatric HIV infection. J. Virus Erad. 2016; 2(4): 208-14.
25. Lichtner M., Cicconi P., Vita S., Cozzi-Lepri A., Galli M., Lo Caputo S., et al. Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients. J. Infect. Dis. 2015; 211(Pt. 2): 178-86.
Problems of Virology. 2017; 62: 162-168
DIMERIC BISBENZIMIDAZOLES SUPPRESS THE HERPES SIMPLEX VIRUS AND HUMAN CYTOMEGALOVIRUS INFECTIONS IN CELL СULTURES
https://doi.org/10.18821/0507-4088-2017-62-4-162-168Abstract
References
1. Looker K.J., Magaret A.S., May M.T., Turner K.M., Vickerman P., Gottlieb S.L. et al. Global and Regional Estimates of Prevalent and Incident Herpes Simplex Virus Type 1 Infections in 2012. PLoS One. 2015; 10(10): e0140765.
2. James S.H., Kimberlin D.W. Neonatal herpes simplex virus infection: epidemiology and treatment. Clin. Perinatol. 2015; 42(1): 47-59.
3. Barrett M.P., Gemmell C.G., Suckling C.J. Minor groove binders as anti-infective agents. Pharmacol. Ther. 2013; 139: 12-23.
4. Wilson W. D., Nguyen B., Tanious F. A., Mathis A., Hal J.E., Stephens C.E. et al. Dications that target the DNA minor groove: compound design and preparation, DNA interactions, cellular distribution and biological activity. Curr. Med. Chem. Anticancer. Agents. 2005; 5(4): 389-408.
5. Meikhi B. Virusologiya. Metody: Per. s angl. M.: Mir; 1988
6. Latt S.A. Optical studies of metaphase chromosome organization. Annu. Rev. Biophys. Bioeng. 1976; (5): 1-37.
7. Teng M.K., Usman N., Frederick C.A., Wang A.H. The molecular structure of the complex of Hoechst 33258 and the DNA dodecamer d(CGCGAATTCGCG). Nucleic. Acids. Res. 1988; (16): 2671.
8. Vega M.C., Saez I.G., Aymami J., Eritja R., van der Marel G.A., van Boom J.H., et al. Three-dimensional crystal structure of the A-tract DNA dodecamer d(CGCAAATTTGCG) complexed with the minor-groove-binding drug Hoechst 33258. Eur. J. Biochem. 1994; 222: 721.
9. Chiang S.Y., Welch J.J., Rauscher F.J., Beerman T.A. Effects of minor groove binding drugs on the interaction of TATA box binding protein and TFIIA with DNA. Biochemistry. 1994; (33): 7033-40.
10. Chiang S.Y., Welch J.J., Rauscher F.J., Beerman T.A. Effect of DNA-binding drugs on early growth response factor-1 and TATA box-binding protein complex formation with the herpes simplex virus latency promoter. J. Biol. Chem. 1996; 271: 23999-4004.
11. Chen A.Y., Yu C., Gatto B., Liu L.F. DNA minor groove-binding ligands: a different class of mammalian DNA topoisomerase I inhibitors. Proc. Nat. Acad. Sci. USA. 1993; 90: 8131-5.
12. Zhang X., Zhang S.C., Sun D., Hu J., Wali A., Pass H., et al. New insight into the molecular mechanisms of the biological effects of DNA minor groove binders. PLoS One. 2011; 6(10): e25822.
13. Woynarowski J.M., McHugh M., Sigmund R.D., Beerman T.A. Modulation of topoisomerase II catalytic activity by DNA minor groove binding agents distamycin, Hoechst 33258, and 4’,6-diamidine-2-phenylindole. Mol. Pharmacol. 1989; 35: 177-82.
14. Soderlind K.J., Gorodetsky B., Singh A.K., Bachur N.R., Miller G.G., Lown J.W. Bis-benzimidazole anticancer agents: targeting human tumour helicases. Anticancer. Drug Design. 1999; 14: 19-36.
15. Martin R.F., Broadhurst S., D’Abrew S., Budd R., Sephton R., Reum M., et al. Radioprotection by DNA ligands. Br. J. Cancer Suppl. 1996; 74(27): 99-101.
16. Lyubimova N.V., Coutlas P.G., Yuen K., Martin R.F. In vivo radioprotection of mouse brain endothelial cells by Hoechst 33342. Br. J. Radiol. 2001; 74: 77-82.
17. Susova O.Yu., Ivanov A.A., Morales Ruiss S.S., Lessovaya E.A., Gromyko A.V., Strel'tsov S.A. i dr. Uzkoborozdochnye dimernye bisbenzimidozoly ingibiruyut in vitro svyazyvanie s DNK eukarioticheskoi DNK topoizomerazy I. Biokhimiya. 2010; 75(6): 781-8
18. Cherepanova N.A., Ivanov A.A., Maltseva D.V., Minero A.S., Gromyko A.V., Streltsov S.A., et al. Dimeric bisbenzimidazoles inhibit the DNA methylation catalyzed by the murine Dnmt3a catalytic domain. J. Enzyme Inhib. Med. Chem. 2011; 26(2): 295-300.
19. Tunitskaya V.L., Mukovnya A.V., Ivanov A.A., Gromyko A.V., Ivanov A.V., Streltsov S.A., et al. Inhibition of the helicase activity of the HCV NS3 protein by symmetrical dimeric bis-benzimidazoles. Bioorg. Med. Chem. Lett. 2011; 21(18): 5331-5.
20. Popov K.V., Egorova E.I., Ivanov A.A., Gromyko A.V., Zhuze A.L., Bol'sheva N.L. i dr. Dimernye bisbenzimidozol'nye krasiteli na osnove Hoechst 33258 novye DNK-spetsifichnye flyuorokhromy dlya tsitogenetiki cheloveka i rastenii. Biologicheskie membrany. Zhurnal membrannoi i kletochnoi biologii. 2008; 25(3): 173-80
21. Looker K.J., Magaret A.S., Turner K.M., Vickerman P., Gottlieb S.L., Newman L.M. Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012. PLoS One. 2015; 10(1): e114989
22. Klimova R.R., Malinovskaya V.V., Guseva T.S., Parshina O.V., Getiya E.G., Degtyareva M.V. i dr. Vliyanie gerpesvirusnykh infektsii na uroven' provospalitel'nykh tsitokinov u nedonoshennykh novorozhdennykh detei. Voprosy virusologii. 2011; (4): 23-6
23. Moore M.D., Bunka D.H., Forzan M., Spear P.G., Stockley P.G., McGowan I., et al. Generation of neutralizing aptamers against herpes simplex virus type 2: potential components of multivalent microbicides. J. Gen. Virol. 2011; 92(7): 1493-9.
24. Slyker J.A. Cytomegalovirus and paediatric HIV infection. J. Virus Erad. 2016; 2(4): 208-14.
25. Lichtner M., Cicconi P., Vita S., Cozzi-Lepri A., Galli M., Lo Caputo S., et al. Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients. J. Infect. Dis. 2015; 211(Pt. 2): 178-86.
